Journal article
The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial
S Zoungas, J Chalmers, AP Kengne, A Pillai, L Billot, B de Galan, M Marre, B Neal, S Harrap, N Poulter, A Patel
Diabetes Research and Clinical Practice | Published : 2010
Abstract
The aim of these analyses was to examine the efficacy of the intensive gliclazide MR-based glucose lowering regimen used in the ADVANCE trial in lowering the level of glycated haemoglobin (HbA1c). All 11,140 randomised patients were included in analyses of treatment efficacy. Treatment efficacy was also examined in subgroups defined by baseline characteristics and treatments. At the end of 5 years follow-up, the mean HbA1c was reduced from 7.5% at baseline to 6.5% in those on intensive glucose control and to 7.3% in those on standard glucose control. With intensive glucose lowering greater proportions achieved HbA1c levels of ≤7.0%, ≤6.5% and ≤6.0%. With intensive glucose lowering substantia..
View full abstractGrants
Funding Acknowledgements
[ "John Chalmers holds a research grant from Servier as principal investigator for ADVANCE. Sophia Zoungas, John Chalmers, Anushka Patel, Bastiaan de Galan, Michel Mane, Bruce Neal, Stephen Harrap, and Neil Poulter have received lecturing fees from Servier. John Chalmers and Michel Mane have served on Servier Advisory Boards.", "The ADVANCE trial was supported by grants from the National Health and Medical Research Council of Australia and from Servier International, administered through the University of Sydney. ADVANCE was an investigator-initiated study that was designed, conducted, analysed, and interpreted independently of both sponsors, neither of which was represented on the study Management Committee. The authors had final responsibility for the preparation of the manuscript and for the decision to submit for publication.", "S. Zoungas was supported by a National Health and Medical Research Council of Australia Health Professional Research Fellowship. A. Patel was supported by a National Heart Foundation of Australia Career Development Award." ]